<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="45220">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02517619</url>
  </required_header>
  <id_info>
    <org_study_id>EGP-437-006</org_study_id>
    <nct_id>NCT02517619</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Non-Infectious Anterior Uveitis</brief_title>
  <acronym>EGP-437-006</acronym>
  <official_title>A Prospective, Multi-Center, Randomized, Double-Masked, Positive Controlled, Phase 3 Clinical Trial Designed to Evaluate the Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution Compared to Prednisolone Acetate Ophthalmic Suspension (1%) in Patients With Non-Infectious Anterior Segment Uveitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eyegate Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eyegate Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of ocular iontophoresis
      with dexamethasone phosphate ophthalmic solution EGP-437 using the EyeGate® II Drug Delivery
      System (EGDS) compared to prednisolone acetate ophthalmic suspension (1%) in patients with
      non-infectious anterior segment uveitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a Phase 3, randomized, double-masked, parallel arm, positive-controlled
      non-inferiority study, in which up to 250 subjects (approximately 125 subjects per treatment
      arm) will be enrolled at up to 60 clinical sites. Patients with non-infectious anterior
      segment uveitis who are interested in participating in the study will be provided an
      informed consent form prior to screening. Screening/Baseline procedures which include BCVA,
      slit lamp examination, fundus exam, IOP by tonometry will be used to determine eligibility.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">October 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects with an AC cell count of zero at Day 14</measure>
    <time_frame>Day 14 ± 2 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Anterior Uveitis</condition>
  <arm_group>
    <arm_group_label>Dexamethasone Phosphate Ophthalmic Solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexamethasone phosphate ophthalmic solution (40 mg/mL)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prednisolone Acetate Ophthalmic (1%)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prednisolone Acetate Ophthalmic (1%)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone Phosphate Ophthalmic Solution</intervention_name>
    <description>40 mg/mL</description>
    <arm_group_label>Dexamethasone Phosphate Ophthalmic Solution</arm_group_label>
    <other_name>EGP-437</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone Acetate Ophthalmic (1%)</intervention_name>
    <description>Prednisolone Acetate (1%)</description>
    <arm_group_label>Prednisolone Acetate Ophthalmic (1%)</arm_group_label>
    <other_name>Pred Acetate (1%)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 12 to 85 years with a diagnosis of non-infectious anterior segment uveitis
             defined as an AC cell count of ≥ 11 cells

          2. Receive, understand, and sign a copy of the written informed consent form

          3. Be able to return for all study visits and willing to comply with all study-related
             instructions

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John D. Sheppard, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Study Principal Investigator</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lisa Brandano</last_name>
    <email>lbrandano@eyegatepharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carol Assang</last_name>
    <email>cassang@eyegatepharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Virginia Eye Consultants</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 1, 2016</lastchanged_date>
  <firstreceived_date>August 5, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Iontophoresis</keyword>
  <keyword>Ophthalmology</keyword>
  <keyword>Non-Infectious Anterior Segment Uveitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Uveitis</mesh_term>
    <mesh_term>Uveitis, Anterior</mesh_term>
    <mesh_term>Iridocyclitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
